Medtronic Cardiovascular
Trial Pipeline
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347
TTVR Early Feasibility Study
NCT04433065
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
NCT03242642
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755
Harmony TPV Post-Approval Study
NCT05077774
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
NCT04722250
Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study
NCT03635424
Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients
NCT02701283
Transcatheter Mitral Valve Replacement System (TMVR) Pilot Study and The Early Feasibility Study of the TMVR Transseptal System
NCT02322840
Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement
NCT01675440
ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)
NCT01534819
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
NCT01586910
DISSECT-N Post Market Data Collection Registry
NCT04267055
Medtronic CoreValve Evolut R U.S. Clinical Study
NCT02207569
Study to Evaluate the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections
NCT01114724
Post-Approval Trial of the Talent™ Abdominal Stent Graft to Treat Aortic Aneurysms
NCT00816062
Valor II: The Valiant Thoracic Stent Graft System Clinical Study
NCT00413231
What the Pipeline for Medtronic Cardiovascular Shows
According to the ClinicalTrials.gov registry, Medtronic Cardiovascular is linked to 49 US clinical trials across every stage of research activity. Of those, 35 studies are currently recruiting — about 71% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 10% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Medtronic Cardiovascular reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Medtronic Cardiovascular is Severe Aortic Stenosis with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.